ACET - Aceto Corporation
| Previous Close | 0.1345 |
| Open | 0.1590 |
| Bid | 0.0000 x 4000 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.1330 - 0.1650 |
| 52 Week Range | 0.1330 - 0.1650 |
| Volume | 6,744,238 |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•3 months ago
ACETO Completes the Sale of Its Chemicals Business Assets
ACETO Corporation (ACETQ) announced today that it has completed the previously disclosed sale of its chemicals business assets to an affiliate of New Mountain Capital, a leading growth-oriented investment firm with over $20 billion in assets under management.
- GlobeNewswire•3 months ago
ACETO Completes the Sale of Rising Pharmaceuticals
PORT WASHINGTON, N.Y., April 22, 2019 -- ACETO Corporation (Nasdaq: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human.
- GlobeNewswire•3 months ago
ACETO to Sell its Chemicals Business Assets to New Mountain Capital
ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management. The asset purchase agreement was entered into following the conclusion of a court-supervised sale process conducted under Section 363 of the U.S. Bankruptcy Code. Under that process, an asset purchase agreement between Aceto and NMC was executed, dated February 18, 2019, to sell the chemical business assets as the “stalking horse agreement”.
- GlobeNewswire•3 months ago
ACETO Receives Court Approval of “Stalking Horse” Agreement to Sell Rising Pharmaceuticals to Shore Suven Pharma, Inc.
ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has received approval from the U.S. Bankruptcy Court to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc. for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business, on a cash-free and debt-free basis. The sale was conducted through a Court-supervised process under Section 363 of the Bankruptcy Code. Under that process, Shore Suven Pharma’s purchase agreement served as the “stalking horse agreement” and an auction would have been conducted had the Company received qualified offers from other bidders reflecting potentially higher and/or otherwise better terms.
GuruFocus.com•4 months ago6 Poorly Performing Stocks
The return on equity of -211.13% and return on assets of -41.80% are underperforming 84% of companies in the Global Drug Manufacturers - Specialty and Generic industry. The company's largest guru shareholder is Jim Simons (Trades, Portfolio)' Renaissance Technologies with 4.75% of outstanding shares, followed by Chuck Royce (Trades, Portfolio) with 1.53%. The return on equity of -0.71% and return on assets of -0.42% are underperforming 72% of companies in the Global Coal industry.
- GlobeNewswire•4 months ago
ACETO Enters into “Stalking Horse” Agreement to Sell Rising Pharmaceuticals
ACETO Corporation (ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has entered into a “stalking-horse” asset purchase agreement with Shore Suven Pharma, Inc. to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business on a cash-free and debt-free basis. Shore Suven Pharma, Inc. is a joint venture between Suven Life Sciences Limited, an India-based provider of contract research and manufacturing services for the global life sciences industry, and Shore Pharma Investments, LLC, a company founded by Vimal Kavuru to acquire generic drug assets.
- ACCESSWIRE•5 months ago
Watch These Four Healthcare Stocks Set The Pace on Thursday
Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aceto Corporation (ACET), OPKO Health Inc (OPK), and Midatech Pharma plc (NASDAQ:MTP) represent 4 healthcare stocks to pay attention to on Thursday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is laser-focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to champion products and services meant to improve the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced the launch of at technology-enabled mental health counseling service for patients in urban centers and remote and underserved populations.
- GlobeNewswire•5 months ago
ACETO Announces Receipt of Nasdaq Notice Due to Delay in Filing Form 10-Q for the Fiscal Quarter Ended December 31, 2018
PORT WASHINGTON, N.Y., Feb. 20, 2019 -- ACETO Corporation (Nasdaq: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health.
- GlobeNewswire•5 months ago
ACETO Announces Proposed Sale of its Chemicals Business Assets to New Mountain Capital for $338 million
ACETO and its U.S. Subsidiaries File Voluntary Chapter 11 Petitions to Facilitate SaleSecures Commitment for Debtor-in-Possession Financing to Support Normal Course.
- GlobeNewswire•6 months ago
New Research Coverage Highlights NiSource, Callaway Golf, TEGNA, The Manitowoc, CTS, and Aceto — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of ACET earnings conference call or presentation 9-Nov-18 2:00pm GMT
Q1 2019 Aceto Corp Earnings Call
- Business Wire•7 months ago
Robbins Arroyo LLP: Lawsuit Says Aceto Corporation (ACET) Misled Shareholders
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Aceto Corporation (ACET) have sued the company's officers and directors for breaches of their fiduciary duties between August 25, 2017 and April 18, 2018. Aceto develops, markets, sells, and distributes finished dosage form generic pharmaceuticals and nutraceutical products, among other products. According to the complaint, Aceto assured investors that the company's internal controls over financial reporting were effective.
- Simply Wall St.•7 months ago
Could The Aceto Corporation (NASDAQ:ACET) Ownership Structure Tell Us Something Useful?
If you want to know who really controls Aceto Corporation (NASDAQ:ACET), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...
- Associated Press•8 months ago
Aceto: Fiscal 1Q Earnings Snapshot
The Port Washington, New York-based company said it had a loss of 59 cents per share. The chemical company posted revenue of $164.4 million in the period. The company's shares closed at $2.03. A year ago, ...
- GlobeNewswire•8 months ago
ACETO Reports Fiscal 2019 First Quarter Results
PORT WASHINGTON, N.Y., Nov. 08, 2018 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health.
- GlobeNewswire•8 months ago
ACETO Corporation Adopts Rights Plan Designed to Preserve Valuable Net Operating Loss Carryforwards and Other Tax Benefits
ACETO Corporation (ACET) today announced that its Board of Directors has adopted a tax asset protection rights plan (the “Rights Plan”). The Rights Plan is designed to preserve ACETO’s net operating loss carryforwards (NOLs) and other significant tax benefits which may be available to reduce potential future tax liabilities. ACETO’s Board determined that the Rights Plan was warranted and in the best interests of all stockholders due to the substantial dollar amount of the NOLs and other tax assets and the importance of these potential benefits for future cash flows. The Rights Plan is similar to the tax asset protection rights agreements adopted by numerous other public companies seeking to protect their NOLs and other tax benefits. The Rights Plan and the rights issued under the Rights Plan will expire on November 5, 2021, or on an earlier date if certain events occur, as described more fully in the Rights Plan.
- ACCESSWIRE•9 months ago
Update: Lawsuit for Investors in Aceto Corporation (NASDAQ: ACET) Shares Announced by Shareholders Foundation
SAN DIEGO, CA / ACCESSWIRE / October 22, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares Aceto Corporation (NASDAQ: ACET). The plaintiff seeks ...